Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kramer

Showing results (201-210 of 240) with videos related to

Pageof 24
Sort By:
Acta Neuropathologica|March 28, 2021
Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signatureFlorian Ingelfinger, Sinduya Krishnarajah, Michael Kramer, et al.
Acta Neuropathologica|August 18, 2021
Correction to: Single‑cell profiling of myasthenia gravis identifies a pathogenic T cell signatureFlorian Ingelfinger, Sinduya Krishnarajah, Michael Kramer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
Human Brain Mapping|May 1, 2007
Genes, maternal smoking, and the offspring brain and body during adolescence: design of the Saguenay Youth StudyZdenka Pausova, Tomás Paus, Michal Abrahamowicz, et al.
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Haematologica|August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Haematologica|February 13, 2023
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trialLeo Ruhnke, Christoph Röllig, Sylvia Herold, et al.
Pageof 24

Showing results (201-210 of 240) with videos related to

Sort By:
Pageof 24
Acta Neuropathologica|March 28, 2021
Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signatureFlorian Ingelfinger, Sinduya Krishnarajah, Michael Kramer, et al.
Acta Neuropathologica|August 18, 2021
Correction to: Single‑cell profiling of myasthenia gravis identifies a pathogenic T cell signatureFlorian Ingelfinger, Sinduya Krishnarajah, Michael Kramer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
Human Brain Mapping|May 1, 2007
Genes, maternal smoking, and the offspring brain and body during adolescence: design of the Saguenay Youth StudyZdenka Pausova, Tomás Paus, Michal Abrahamowicz, et al.
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Haematologica|August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Haematologica|February 13, 2023
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trialLeo Ruhnke, Christoph Röllig, Sylvia Herold, et al.
Pageof 24